key: cord-0905793-293pv10w
authors: Adli, Abolfazl; Rahimi, Mandana; Khodaie, Reza; Hashemzaei, Niloofar; Hosseini, Sayed M.
title: Role of genetic variants and host polymorphisms on COVID‐19: From viral entrance mechanisms to immunological reactions
date: 2022-02-08
journal: J Med Virol
DOI: 10.1002/jmv.27615
sha: 35aa15da342b27353cb486a58799e66ea2cf67e1
doc_id: 905793
cord_uid: 293pv10w

Coronavirus disease 2019 (COVID‐19), caused by a highly pathogenic emerging virus, is called severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Knowledge regarding the pathogenesis of this virus is in infancy; however, investigation on the pathogenic mechanisms of the SARS‐CoV‐2 is underway. In COVID‐19, one of the most remarkable characteristics is the wide range of disease manifestation and severity seen across individuals of different ethnic backgrounds and geographical locations. To effectively manage COVID‐19 in the populations, beyond SARS‐CoV‐2 detection, serological response assessment, and analytic techniques, it is critical to obtain knowledge about at‐risk individuals and comprehend the identified variations in the disease's severity in general and also in the populations' levels. Several factors can contribute to variation in disease presentation, including population density, gender and age differences, and comorbid circumstances including diabetes mellitus, hypertension, and obesity. Genetic factors presumably influence SARS‐CoV‐2 infection susceptibility. Besides this, COVID‐19 has also been linked with a higher risk of mortality in men and certain ethnic groups, revealing that host genetic characteristics may affect the individual risk of death. Also, genetic variants involved in pathologic processes, including virus entrance into cells, antiviral immunity, and inflammatory response, are not entirely understood. Regarding SARS‐CoV‐2 infection characteristics, the present review suggests that various genetic polymorphisms influence virus pathogenicity and host immunity, which might have significant implications for understanding and interpreting the matter of genetics in SARS‐CoV‐2 pathogenicity and customized integrative medical care based on population investigation.

serine 2 (TMPRSS2), a cleavage that promotes the fusing of membranes (between viral and cellular membranes) viral propagation in the cells infected with SARS-CoV-2. [10] [11] [12] This procedure might include human exopeptidase CD26, widely known as Dipeptidylpeptidase 4 (DPP4), a crucial immunostimulatory component for hijacking and virulence. 13 Age above 60, male gender, and the existence of comorbid metabolic disorders such as being overweight, hypertension, and diabetes have been implicated in the COVID-19 development and severity. [14] [15] [16] Nonetheless, there is a continuous exploration of biological variables related to COVID-19 evolution. Genetic variables may affect the development and course of infectious diseases, according to evidence. 17 Multiple genetic polymorphisms, mostly single-nucleotide polymorphisms (SNPs), have been linked to this setting's predisposition to viral respiratory infections. 18 Genetic polymorphism is the hallmark of human biology. 19 Scientists studying disease pathology are completely aware of this, and they often resort to simplifying human disease by establishing animal models that remove this complex facet via years of inbreeding. 19 The immune system is undoubtedly the most significantly influenced by human genetic diversity. 19, 20 Until recently, the pinpoint significance function of genetic composition in SARS-CoV-2 related pathology has been understudied, but pro-inflammatory-related processes have been implicated. 8, 9, 21 Identifying the host genetic elements implicated in SARS-CoV-2 disease might contribute to the emergence of innovative therapeutic approaches for the prophylaxis and clinical monitoring of this disease using a precision medicine strategy. 22, 23 As there is a paucity of information on genetics and SARS-CoV-2 pathogenicity, the objectives of this paper were to explore the role of genetic variants and host polymorphisms in specific viral entry and immune responses related to clinical consequences of in humans to design future clinical implementation.

Initially, investigation for SARS-CoV-2 antiviral medications depended solely on the Vero E6 (African green monkey kidney cell line) as the host cell to evaluate inhibitory effects of antiviral candidate drugs on the cytopathic effect (CPE) of the virus. 24 Together with the absence of the expression of TMPRSS2 and ACE2, endogenous unspecified endosomal viral absorption mechanisms are involved for SARS-CoV-2 entrance in Vero E6 and several other types of cells. [24] [25] [26] As a result, a broad range of compounds that regulate endosomal-lysosomal maturation and autophagy processes have been shown to have potent antiviral activity in Vero E6 cells, which might not apply to original epithelial cells from the lung. This opens the possibility that the antiviral suppression observed in Vero E6 assays by many of these drugs toward this virus is limited and in vitro activity and that they are neither relevant nor translatable as SARS-CoV-2 therapies. SARS-CoV-2 and other coronaviruses infect epithelial cells in the mammalian lung by attaching their spike protein to a particular cellular receptor. ACE2, which is present on the lungs and gut epithelial cells and on kidney, heart, and adipose tissues, acts as a cell surface ligand for SARS-CoV-2 and the other related SARS-CoVs. 10, 12, 15, [27] [28] [29] [30] After attaching to the cellular receptor, the spike protein is activated by a host protease at the intersection of its S1 and S2 regions through proteolytic processing. 31 When the newly released S2 domain N-terminus is inserted further into the cellular membrane, the fusion between viral and cellular membranes leads to the transport of viral RNA further into the host cell cytoplasm, wherein viral proliferation may begin. 31 The spike or S protein (as trimers) is located on the surface of SARS-CoV-2 particles, and every one of the S-protein subunits has two domains, which are designated as S1 and S2 on the S protein's structure. 32 The S1 domain interacts with ACE2 receptors, while the S2 domain promotes membrane fusion, which allows the viral particle to enter the cell. 32 SARS-CoV-2 enters the human cell via ACE2 receptors. The S1

domain's receptor-binding domain (RBD) interacts with ACE2 receptors. 32 An in vitro research revealed that SARS-CoV-2 could not infect ACE2 null Vero E6 and Hela cells, implying that this receptor plays a critical role in cellular viral entry. 33 Membrane-bound TMPRSS2 is required for the cleavage of ACE2 and S-protein for viral entrance mediating membrane fusion and therefore performs a significant function in SARS-CoV-2 pathogenesis. Coronaviruses employ many additional cell surface receptors, plus TMPRSS2 and ACE2, to promote cellular entrance; these include DPP4 and furin for Middle East respiratory syndrome coronavirus (MERS-CoV), aminopeptidase N (ANPEP) for Human coronavirus 229E (HCoV-229E), TMPRSS11D for SARS-CoV, and ST6GAL1 (ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 1) and ST3GAL4 for Human coronavirus OC43 (HCoV-OC43) and Human coronavirus HKU1 (HCoV-HKU1). [34] [35] [36] S-protein of SARS-CoV-2 has *80% sequence identity with SARS-CoV, and most of the remaining positions are conserved. Excluding the insertion of Val483 in SARS-CoV-2, the residues across Leu335 and Phe515 of SARS-CoV-2 are similar to those spanning Leu322 and Phe501 of SARS-CoV. This area contains three ACE2 interaction sections, namely CR1, CR2, and CR3, which are located inside a receptor-binding motif (RBM) of SARS-CoV-2 that has *50% sequence similarity with SARS-CoV. 37 The new SARS-CoV-2 virus, like with the SARS, enters cells via the use of the ACE2 protein on the cellular membrane. 38 ACE2 works as an enzyme in the renin-angiotensin system (RAS), regulating blood pressure, fluid balance, and vascular constriction. Angiotensin I (Ang I) produced by renin degradation is transformed to Ang II by the angiotensin-converting enzyme ACE, which activates angiotensin II type I receptors (AT1Rs), leading to oxidative stress, proinflammatory signaling, elevated blood pressure, and vasoconstriction. A strong affinity for Ang II exists between the ACE2 enzyme and it, resulting in the formation of Ang II (1-7). As a result, ACE2 mitigates the effects of Ang II and protects against chronic conditions such as cardiovascular disorder, hypertension, and diabetes. 39 Significantly, higher concentrations of Ang II are found in COVID-19 ADLI ET AL. | 1847 individuals who have never had an ACE or an ARB, and elevated concentrations are linked with enhanced severity. 40 It is also necessary for SARS-CoV-2 virus entrance to be initiated by the serine protease TMPRSS2, which could be partly inhibited in certain cell types by the serine protease inhibitor camostat mesylate, which is also effective in some cell types. 38 It has been observed that when camostat inhibition of TMPRSS2 was coupled with an antagonist of endosomal cysteine proteases, cathepsin B/L, complete inhibition was accomplished. 10 3 | IMMUNE RESPONSE TO SARS-COV-2

The body's immune system recognizes the entire virus or its surface epitope once inside the target cells, inducing an immune response (innate or adaptive). 2, 20, 41, 42 When a virus is initially detected, immune cells' pathogen recognition receptors (PRRs), mainly Toll-like receptors (TLRs) 3, 7, and 8, synthesize more interferon (IFN). 1, 20 The nonstructural proteins of SARS-CoV and MERS-CoV disrupt the activity of host innate immunity, affecting total cytokine generation. 43, 44 The humoral immunity to SARS-CoV-2 is similar to other coronavirus diseases, producing IgG and IgM formation. 45 B cells provide an initial response to the N protein when infected with SARS-CoV.

Nevertheless, antibodies toward S protein may be identified 4-8 days after the onset of first manifestations. 46, 47 Despite being smaller than S protein, the N protein is highly immunogenic. As it lacks glycosylation sites, it produces N-specific neutralizing antibodies at the initial stages of severe disease. 48 Individuals infected with SARS-CoV were shown to have IgA, IgG, and IgM antibodies specific to the virus at different times after the onset of symptoms. 48 Anti-S-RBD IgG was found in all 16 SARS-CoV-2 cases in an observational research investigation, while anti-N IgG and anti-S-RBD IgM were recognized in 15 cases and anti-N IgM in 14 cases. 49 According to a research study on pediatric patients, five out of six kids had a protecting humoral immunity, including neutralizing IgG and IgM antibodies against the SARS-CoV-2 N and S-RBD proteins. 50 In responding to viral diseases, our immune system acts in a series of activities that fight the invading virus. 4, 51 The innate immunity is first activated, which detects and destroys foreign viral material and initiates a signaling cascade that restricts virus transmission to adjacent cells. 51 Although it is difficult to show experimentally, innate immunity may play a significant role in containing SARS-CoV-2 in certain instances, such as subclinical or moderate diseases in children and adolescents. 52 T cells that recognize processed Ag expressed by MHC molecules (class I and II) are promptly engaged to eliminate infected cells and coordinate the immune reaction, whereas the IgM reaction proceeds simultaneously. Multivalent antiviral IgM is the first isotype generated toward viral diseases and therefore plays an essential role in the early phases of the disease. 51 During SARS-CoV-2 recovery, immunophenotyping of peripheral B cells revealed that both un-switched IgM+ memory B cells and classical switched B cells are components of the circulatory memory population and may hold steady for months. 53 Convalescent people have a memory of anti-SARS-CoV-2-reactive T cells. 54, 55 On the other hand, cross-reactive T cells were found in a large proportion of pre-pandemic and seronegative people who had not been subjected to SARS-CoV-2, indicating that T cells seem to be more promiscuity than B cells. [54] [55] [56] [57] [58] According to findings, crossreactive IgM memory B cells evoked by prior exposures to pandemic COVID-19 could be involved in the reaction to SARS-CoV-2 in a subset of individuals, while the IgG reaction, particularly to the spike glycoprotein, is particular for SARS-CoV-2. 59, 60 To determine if past reactions to epidemic CoVs offer any degree of protection against symptomatic COVID-19, additional research must be conducted, and the issue will be explored in more depth later onwards.

Human genetic makeup refers to the genetic differences between people and groups and includes alterations spanning from SNPs to massive genome alternations and epigenetic modifications. 61 Thus according to commonly accepted evidence, human genetic variation is believed to be about 0.1%, which means that any two people vary on average by around 1 in 1000 nucleotides. However, some current findings indicate a greater rate of genetic variation in the human community. 62, 63 This is an interesting topic since it may provide insight into human history and evolution and enhance wellbeing. Individual and population genetic variations may influence diseases predisposition, resistance to disease and pathogens, and responsiveness to pharmacological therapies. Recognizing and tracking such variations is critical for understanding the foundation and processes of different illnesses, finding novel therapeutic strategies, and developing new therapeutics. The distribution of genetic diversity inside and across human societies results from tens of thousands of years of demographic background and evolution that altered the human genome as an adaptive reaction to dietary restrictions, the environment, and pathogens. 64, 65 Based on the current corpus of findings, newer genomics tools and methods will allow us to comprehend these distinctions better and use the information in biomedicine, from finding novel genes causing the disease to develop novel therapeutics. 66 Infectious diseases have been identified as one of the most significant evolutionary forces that have influenced and shaped the human genome throughout time. Pathogen-induced infections have been and continue to be the leading cause of death in many parts of the world, acting as a selective pressure that favors genetic variants that confer disease resistance over those that do not.

Haldane initially proposed this hypothesis, noting that heterozygosity for some hematological diseases correlates with malaria resistance. 67 Furthermore, naturally occurring resilience to human immunodeficiency virus (HIV) disease is an instance of how the finding of genetic resistance may act as a foundation for future treatment. 61 CCR5-32 (chemokine receptor 5-CCR5), the cell surface ligand that functions as an HIV coreceptor, has a 32-base deletion, which results in resistance to HIV. 61, 68 The existence of this deletion inhibits viral entry and receptor expression on CD4 1T cells, giving complete HIV protection in homozygous carriers and modest resistance toward disease development in heterozygous carriers. 61 Following the finding that suppressing CCR5 expression may render cells resistant to HIV infection, this discovery has opened the path for the development of stem cell-based therapies. This method was initially shown to be effective over a decade earlier, whenever cases who got stem cells from a CCR5-32 homozygous donor maintained HIV-free. 69 

As among the most studied risk factors for autoimmune disorders, the variation in the human leukocyte antigens (HLAs) gene has been identified as one of the most important. 71 These genes code for MHC molecules, which are responsible for presenting antigens to Tlymphocytes on the cell surface. 72 The HLA system is among the first to be exposed to exogenous antigens, which indicates its influence on future immunological responses, including autoimmune disorders. 73 According to a study, the HLA-C*07:29 and B*15:27 alleles have been related to SARS-CoV-2 vulnerabilities in the Han ethnicity. 74 MHC-B*46:01 has the lowest affinity for coronavirus proteins, according to an in silico research, which is why those with the HLA-B*46:01 genotype may be more vulnerable to COVID-19, as was previously shown for SARS-CoV. 75 These molecules of MHC (including MHC-A*02:02, -B*15:03, and -C*12:03) demonstrated the most potent ability to express evolutionary conserved SARS-CoV-2 peptides carried by human coronaviruses. This suggests that they could offer cross-protection through T-cell immunity. 75 In addition, MHC-A*25:01 and C*01:02, which have a low affinity for coronavirus proteins, were discovered in this investigation. Moreover, Secolin et al. 76 in the Brazilian population determined HLA alleles formerly correlated with the COVID-19 reaction at loci DQB1 and DRB1.

Their findings might cause altering the rate of infection or reaction to infection by SARS-CoV-2 and should be further explored in cases with this infection. 76 Six genes in the 3p21.31 region, including SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6, and XCR1, were linked to the severity of the disease in a genome-wide analysis of individuals from Spain and Italy. 77 The CXCR6 gene, which encodes the chemokine receptor 6 with the CXC motif (CXCR6), which regulates the precise placement of memory CD8+T lymphocytes (lung tissue-resident) that are specific for respiratory tract infections such as influenza viruses, was found to be expressed at a lower level in the individuals who participated in the research. 78 It has also been shown that upregulation of SLC6A20, which produces sodium/imino-acid (proline) transporter 1 (SIT1) and physiologically interfaces with ACE2, the cellular ligand of SARS-CoV-2, seems to be statistically crucial in patients with COVID-19. 79 Additional research investigated the HLA-genotyping of seven distinct HLA locus (including HLA-A, -C, -B, -DRB1, -DQA1, -DQB1, and -DPB1) and the connection between them and COVID-19 severity. They identified no link between vulnerability to serious COVID-19 and the number of HLA-alleles. CCR9 gene, which generates a chemokine ligand that is both homeostatic and proinflammatory, is one of the genes distinguished among other genes studied. This receptor is found to be implicated in the pathophysiology of many forms of pneumonia, and its production is elevated during the early stages of respiratory inflammation. Several types of pneumonia have been discovered to be mediated by this receptor, and its synthesis is heightened during the initial phases of inflammation in respiratory disease. 80 Lu et al. 81 diseases. 89, 90 This protein is involved in viral invasion and is linked to the COVID-19 severity and the cytokine storm. 91 

Interindividual heterogeneity in vulnerability to COVID-19 disease has been linked to the existence of genetic variants in numerous genes, particularly those that code for proteins involved in the pathogenicity. 92 This section gives a brief overview of the many genes involved in SARS-CoV-2 illness and their association with disease severity (Table 1) .

ACE is the enzyme that converts angiotensin-2 to angiotensin (1-7) from 114. It has been shown that nearly all organs, including the lungs, liver, kidney, vascular system, and other organs, express ACE2. 115, 116 The cellular receptor for SARS-CoV-2 infection is considered to be ACE2. 44 The COVID-19 attaches to target cells via the ACE2 receptor, facilitating COVID-19 adherence, invading, and penetrating. 117 Several receptors may be utilized, although the virus prefers ACE2 and has lower affinities affinity for Glucose-Regulate Protein 78 (Grp78) and CD147 as an additional ligand. 116 The amount of ACE2 expression in males is substantially more significant than in females, which may underlie the male preponderance of COVID-F I G U R E 1 Diversity of type I IFN production and life-threatening COVID-19 pneumonia. It has been demonstrated that variants at the TLR3-and IRF7-dependent type I IFN immunity are related to life-threatening COVID-19 pneumonia and asymptomatic infection. 87 COVID-19, coronavirus disease 2019; IRF7, interferon regulatory factor 7; IFN, interferon; TLR3, toll-like receptor 3 (TLR3) 19 . 118, 119 The effects of ACE2 polymorphism on SARS-CoV-2 pathogenesis are illustrated in Figure 2 .

Nevertheless, in another investigation, ACE2 activity was not correlated with a male/female disease severity difference amongst Italian subjects with COVID-19. 121 Another researcher discovered similar findings, revealing no differences in ACE2 gene expression across age or genders (male vs. female) categories. 122 ACE2 gene is highly polymorphic; several polymorphisms in ACE2 have been associated with higher ACE2 protein production and are more prevalent in the East Asian populations. 117, 123, 124 It is not just that, but the ACE deleting allele, which is related to changes in ACE synthesis, affects the propagation of the virus and the consequences of COVID-19 disease, particularly in Asian communities. 125, 126 According to Stawisk's research, numerous genetic polymorphisms in ACE2 are linked with COVID-19 susceptibility. 127 Some ACE2 gene variants may also affect neurological sequelae frequencies in COVID-19 cases. 128 In contrast, Delanghe et al. 129 could not find a connection amongst deletion allele occurrence of the ACE I/D variant in European, North African, and Middle Eastern countries and COVID-19 disease and mortality rates. There was a low prevalence of polymorphisms in the ACE2 gene in a cohort study of 120 individuals in Madrid, and there was no connection between this gene and COVID-19. 130 Many variables, including genetic makeup, lifestyle, regional and cultural variations across groups, demographic features of the population (gender, age), and comorbidity, may explain the conflicting findings of these research.

There are 26 exons in the ACE gene, which is located on chromosome 17q35. 131 

The DPP4 is another receptor for coronaviruses, also identified as CD26, which is the primary receptor for MERS-CoV cell entrance. 136 Furthermore, CD26 has been identified as a cellular ligand for SARS-CoV-2 entrance into human cells. 137 Beyond its potential involvement in the entrance of this virus into the target cell, CD26 has been linked to obesity, insulin resistance, and hypertension. 138 DPP4 blockers were used to treat type 2 diabetes mellitus (T2DM) because they enhance the half-life of glucagonlike peptide 1 (GLP-1). 139 Given that diabetes and obesity are essential determinants for COVID-19 development and disease severity, studying DPP4 protein in these individuals may offer valuable information. According to another research, individuals hospitalized with COVID-19 had lower levels of DPP4 than a control group. 140 This study even included a group of sepsis subjects who had no changes in DPP4 levels, indicating that the SARS-CoV-2 infection causes a reduction in this protein. The DPP4encoding genes are heterogeneous; a connection between enzyme levels and specific polymorphism genotypes and pathologies such as T2DM and myocardial infarction has been discovered. 141, 142 In this line, a study by Posadas-Sánchez et al. 138 discovered the DPP4 level in a sample of COVID-19 cases and determined whether these levels are linked to severity and certain clinical observations. Furthermore, a link between the DPP4 rs3788979 polymorphism and COVID-19 was discovered.

The genetic vulnerability of DPP4 to COVID-19 was investigated, and a connection was discovered between the rs13015258 missense variation in the CD26 gene and vulnerability to COVID-19. The in silico analysis also indicates that the S protein of SARS-CoV-2 interacts with the targets CD26 and TMPRSS2. 137 

The IFITM proteins are important in antiviral protection in adaptive and innate immunity. 143 The IFITM loci in humans are found on chromosome 11p15.5 and include five genes, one of which is IFITM3. 143 IFITM3 inhibits hemifusion between both the viral envelope and the host cellular membranes in a wide range of enveloped viruses, including Marburg virus, influenza A virus, SARS-CoV virus, and Ebola virus. 144 IFITM3 suppresses viral-cell membrane fusion by altering cell membrane flexibility. 145 Previous research has shown that SNPs in the gene IFITM3 might reduce IFITM3's antiviral activity, increasing infection sensitivity and disease severity. 146 In pioneering research, Zhang et al. 88 identified a greater incidence of rs12252 C variants in severe COVID-19 cases than in moderate cases. It was later demonstrated that C-allele carriers of the SNP rs12252 in the Spanish population had a twofold higher risk of COVID-19 relative to a reference population obtained before the pandemic. 105 The reduction of S protein-mediated entrance by IFITM1,

for SARS-CoV-2. 147 SARS-CoV-2 and SARS-CoV-1 have an 82% sequence similarity. 148 Kim Italy 9q34 contains the ABO blood group loci, and blood-group-specific research discovered a stronger connection between being Apositive and having a greater chance of contracting covid19 than previously thought. 109, 110 DBP 4q11q13 It was shown that having higher 25hydroxyvitamin D levels was linked with a considerably reduced amount of total lung participation while having low 25hydroxyvitamin D levels was related to an Turkey Between both the occurrence (per million) and death rates (per million), as well as the GT genotype (P.05), significant positive associations were discovered. In contrast, a significant negative relationship was discovered between both the occurrence (per million) and death rates (per million), as well as the TT genotype atrs7041 locus amongst the communities (p < 0.05). In conclusion, the differences in the occurrence of COVID19 and the death rates associated with it may be linked with the DBP variants rs7041 and rs4588 were shown to have different effects on vitamin D metabolism. 111, 112 GSTT1 1p13. 3 The GSTT1 and GSTM1 deficient variants are linked with an increased risk of various oxidative stress-related complex illnesses.

It is widely recognized that oxidative stress is a significant contributor to the development of viral respiratory diseases. Pulmonary fibrosis is one of the most serious consequences of COVID-19 illness, which is characterized by high levels of oxidative stress in the body.

India Patients with the GSTM1+/+ and GSTT1−/− genotypes had a poor survival rate. These findings recommended that patients with the GSTT1−/− genotype in COVID-19 had a higher death rate. 113 connection between the COVID-19 death rate and the genotype frequencies of the IFITM3 gene's rs6598045 SNP. This is the first research to demonstrate a substantial population-level link between the COVID-19 mortality rate and the IFITM3 gene's ism. 151 In a nutshell, the mechanisms of IFITM-mediated SARC-CoV-2 suppression need more investigation. 152 

TMPRSS2 is another human ligand for the SARC-CoV-2 that performs a pivotal function in viral entry into the target cell. 10 The study of TMPRSS2 activity in human tissues emphasized the significance of expression in lung tissue and the existence of four polymorphisms (rs383510, rs2070788, rs469390c, and rs464397); these variations are considered to have the potential to affect TMPRSS2 expression and performance. 153 According to Cheng et al.'s research, 154 two genetic polymorphisms in this gene (rs2070788 and rs383510) were strongly linked with the risk of influenza. Furthermore, it was discovered that gender could affect TMPRSS2 gene expression in a large Italian cohort. 92 Several genetic polymorphisms in this gene result in higher TMPRSS2 production and are linked to an increased risk of F I G U R E 2 ACE2 polymorphism and effects on SARS-CoV-2 entrance and outcomes. It has been found that the AA genotype of the rs2285666 is mediated to higher ACE2 expression that causes more virus attachment and can affect the infection course. 120 Besides this, the GG genotype of this polymorphism is medicated to higher expression of CCL2, a chemokine that regulates the formation of chemotaxis and inflammatory mediators from macrophages and monocytes. ACE2, angiotensin-converting enzyme 2; CCL2, C-C Motif Chemokine Ligand 2 ADLI ET AL.

| 1857

influenza. 92 Others have been influenced by androgens, which may underlie the gender disparity in severity of COVID-19. 121 cases; however, they did not find a statistically significant relationship between these two factors. In the Cox hazard model, mortality was substantially 2.28-fold greater in individuals with the GSTT1 −/ − polymorphism (p = 0.047). Cases with the GSTM1 +/+ and GSTT1 +/+ polymorphisms died at a lower rate than those with the GSTM1 +/+ genotype (p = 0.02). They demonstrated that participants who were GSTT1 null had a greater risk of SARS-CoV-2 infection than those with GSTT1 present. In East-Asian nations, increased COVID-19

occurrences and deaths were reported, where the GSTT1 null gene was less prevalent than in other genotypes.

In humans, the method for classification of the blood system is called the ABO system, which is comprised of A and (B glycoprotein antigens), as well as polyclonal antibodies toward these antigens in those who do not display the antigens. 160 In addition to red blood cells, A and B antigens may be found on various kinds of cells, such as epithelial cells of the gastrointestinal and respiratory system and endothelium lining the blood vessels. 160 As a result, in addition to RBC transfusions, for organ cell, tissue, and cell transplantation, ABO compatibility is required. 160 Previous research has shown that the ABO blood group variation impacts predisposition to COVID-19, with people in A and O groups getting a more significant and reduced risk, correspondingly. 161 Since then, many investigations have shown a connection between ABO blood groups and SARS-CoV-2, among others, such as Zhao et al., 162 Zietz et al., 163 and Zeng et al. 164 Transporter 1 t (SLC6A20 gene) interacts with the ACE2 protein. 168 The 9q34 locus, which contains the ABO blood type locus, and a blood-type-specific study showed a more vital link among A groups and COVID-19 susceptibility. Moreover, the risk genotypes of the lead variations in 3p21.31 and 9q34.2 were more common in mechanically ventilated cases than to those receiving oxygen augmentation. The connection on 9q34.2 was traced to the ABO gene. 168 In group O, participants had 25% lower blood concentrations of von Willebrand factor (vWF) and factor VIII (FVIII), both of which are required for platelet adhesion, accumulation, and fibrin clot development. 160 The vWF protein is a transporter and stabilizer for FVIII, which is primarily produced in the vascular endothelium and discharged into the circulation. 160, 169 Individuals in the non-O group are at a higher risk of pulmonary embolism, venous thromboembolism, and thrombosis. 169 As a result, ABO variation is related to vascular tone, leakage dysregulation, oxidative damage, and cytokine storm production. As a result, the ABO variant may influence the development of COVID-19 illness via a molecular process that does not require natural antibodies.

A cytokine that has been identified as pro-inflammatory is interleukin 6 (IL-6), which is generated by a wide variety of cells including fibroblasts, keratinocytes, mesangial cells, and macrophages as a response to tissue damage and disease. 170 In instances of SARS-CoV-1, elevated concentrations of IL-6 were found in the acute phase, which was shown to be associated with pulmonary lesions. 171 In response to SARS-CoV-1 invading the respiratory system, IL-6, in particular,

can elicit a hyper-inflammatory (innate) response. 172 Intriguingly, compared to the influenza A virus, SARS-CoV-1 can generate higher concentrations of IL-6 in human epithelial cells. 173 In certain murine viral diseases, IL-6 is protective and vital in the resolution f infection;

but, in others, such as SARS-CoV-1, high concentrations of IL-6 were linked with acute inflammation and were shown to be connected with death in the mice [140] . This also occurs in those diagnosed with SARS-CoV-2: special retrospective and meta-analysis investigations indicate that higher IL-6 and C-reactive protein (CRP) are associated with death and severity of disease in comparison to mild form. [174] [175] [176] According to growing data, critically severe cases with acute respiratory failure and SARS-CoV-2 have either immunological deregulation or a macrophage recruitment disorder, both of which are characterized by pro-inflammatory cytokines. The immunological deregulation, in particular, is mediated by IL-6 rather than interleukin-1 (IL-1) beta. 176 Increased generation of pro-inflammatory cytokines through lymphocyte and monocytes dysfunction with CD4 lymphopenia are two critical characteristics of this immune dysregulation. 176 Increased expression of this cytokine was implicated in the development of SARS-CoV-2 infection and mortality. [177] [178] [179] Research examining the relationship between IL-6 variants and SARS-CoV-2 infection found a link between the IL-6-174C variant and the severity of pneumonia. 180 Also, it suggested that an anti-IL-6R antibody may have been a valuable therapy for SARS-CoV-2. In another research, IL-6 genotypes were shown to predict COVID-19 severity. 180, 181 At the same time, Ravi et al. 182 discovered that the IL-6 rs1800795 G polymorphism was related to SARS-CoV-2 diseases incidence and death.

Vitamin D binding protein (DBP), which is primarily generated in the liver, regulates the circulatory metabolites of vitamin D (free and total metabolites). [183] [184] [185] Indeed, DBP is the most heterogeneous protein, having many variants that significantly impact its biological activities. 183 The two most frequent DBP genotypes, rs4588, and rs7041 have been linked to the development of various clinical disorders, owing to their affinity for vitamin D. 183 According to findings, individuals with the AA genotype at the rs4588 loci had increased plasma concentrations of 25-hydroxyvitamin D (25(OH)D) in their plasma. 186, 187 Subjects with the GG genotype had lower 25(OH)D concentrations following the same dosage of vitamin D treatment. 187 Remarkably, two variants, including rs7041 and rs4588, have been liked to obstructive pulmonary disease (COPD). 188 Another finding indicated that the rs7041 loci were more susceptible to hepatitis C infection. 189 In a different population, DBP genetic variants have been significantly correlated with the enhanced vulnerability to illnesses and vitamin D insufficiency; they might even have a function in COVID-19. [190] [191] [192] According to recent research, the rs7041 locus is linked with a greater incidence of SARS-CoV-2 diseases and death. 193 As a result, the relationship between DBP and COVID-19 genetic variation may be due to the pleiotropic modulatory effects of bioavailability vitamin D concentrations. 186 According to a recent study, these SNPs in the DBP gene, | 1859 pathophysiological conditions. Therefore, the ACE I/D variant might have been a helpful tool for estimating disease progression and intervention results when applied to the COVID-19 to create a population-based treatment development strategy to prevent disease. Also, it seems that the genetic variation in immune cells might influence immunity against SARS-CoV-2. All in all, further investigation with larger cohorts and control subjects should be carried out to understand better the relationship between COVID-19 severity and various polymorphisms and therapeutic response.

The authors declare no conflict of interest.

Abolfazl Adli had the idea for and planned the study and contributed to the writing of the paper. Mandana Rahimi, Reza Khodaieh, and

Niloofar Hashemzaei contributed to the writing of the report. Sayed M. Hosseini contributed to the critical revision of the report. All authors read and approved the final version.

The data supporting this study's findings are available from the corresponding author upon reasonable request. 

The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

Coronavirus disease 2019 (COVID-19): immunological approaches and emerging pharmacologic treatments

A possible pathogenic role of Syndecan-1 in the pathogenesis of coronavirus disease 2019 (COVID-19)

The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19)

In silico analysis of high-risk missense variants in human ACE2 gene and susceptibility to SARS-CoV-2 infection

Idiopathic thrombocytopenic purpura as a hematologic manifestation of COVID-19 infection: a case report

The pursuit of COVID-19 biomarkers: putting the spotlight on ACE2 and TMPRSS2 regulatory sequences

A possible pathogenic correlation between neutrophil elastase (NE) enzyme and inflammation in the pathogenesis of coronavirus disease 2019 (COVID-19)

The role of lovastatin in the attenuation of COVID-19

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection

Bacterial co-infections with SARS-CoV-2

Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

Exploring host genetic polymorphisms involved in SARS-CoV infection outcomes: implications for personalized medicine in COVID-19

Gender preponderance might be associated with the severity of COVID-19 infection

Persistent hiccups after treatment of COVID-19 with dexamethasone: a case report

Evolution, revolution and heresy in the genetics of infectious disease susceptibility

The role of host genetic factors in respiratory tract infectious diseases: systematic review, meta-analyses and field synopsis

Polymorphism in clinical immunology-from HLA typing to immunogenetic profiling

The human immune system against Staphylococcus epidermidis

The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19

Guide for current nutrigenetic, nutrigenomic, and nutriepigenetic approaches for precision nutrition involving the prevention and management of chronic diseases associated with obesity

A brief review on DNA vaccines in the era of COVID-19

SARS-CoV-2 tropism, entry, replication, and propagation: considerations for drug discovery and development

Virus entry by macropinocytosis

Dissection of the influenza A virus endocytic routes reveals macropinocytosis as an alternative entry pathway

Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

The landscape of host genetic factors involved in infection to common viruses and SARS-CoV-2. medRxiv

Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells

Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease

Influenza and SARScoronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts

Coronaviruses -drug discovery and therapeutic options

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention

Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19

High rate of increased level of plasma Angiotensin II and its gender difference in COVID-19: an analysis of 55 hospitalized patients with COVID-19 in a single hospital

The effect of tobramycin incorporated with bismuth-ethanedithiol loaded on niosomes on the quorum sensing and biofilm formation of Pseudomonas aeruginosa

Role of microRNAs in Staphylococcus aureus infection: potential biomarkers and mechanism

A contemporary review on pathogenesis and immunity of COVID-19 infection

Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine

Overview of immune response during SARS-CoV-2 infection: lessons from the past

Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers

Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients

Serological assays for emerging coronaviruses: challenges and pitfalls

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Protective humoral immunity in SARS-CoV-2 infected pediatric patients

Immunity to SARS-CoV-2 induced by infection or vaccination

Natural mucosal barriers and COVID-19 in children

Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration

Glutamine synthetase 1 increases autophagy lysosomal degradation of mutant huntingtin aggregates in neurons, ameliorating motility in a Drosophila Model for Huntington's Disease

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Promiscuous T-cell responses to drugs and drug-haptens

Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells

Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Chapter 8 -Human genetic diversity in health and disease

Adaptive hitchhiking effects on genome variability

Global variation in copy number in the human genome

Challenges in human genetic diversity: demographic history and adaptation

Population genomics: a bridge from evolutionary history to genetic medicine

The pathogenic, therapeutic and diagnostic role of exosomal microRNA in the autoimmune diseases

The rate of mutation of human genes

Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation

HLA-DRB1 the notorious gene in the mosaic of autoimmunity

Immunogenetic predictors of severe COVID-19

The HLA system: genetics, immunology, clinical testing, and clinical implications

Association of HLA class I with severe acute respiratory syndrome coronavirus infection

Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2

Genetic variability in COVID-19-related genes in the Brazilian population

Genomewide association study of severe Covid-19 with respiratory failure

CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways

Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon

Genetic risk factors for death with SARS-CoV-2 from the UK Biobank. medRxiv

Presence of genetic variants among young men with severe COVID-19

Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes

The SARS-CoV S glycoprotein: expression and functional characterization

Host genetic variants potentially associated with SARS-CoV-2: a multipopulation analysis

A MUC5B gene polymorphism, rs35705950-T, confers protective effects in COVID-19 infection. medRxiv

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Interferon-induced transmembrane protein 3 genetic variant rs12252-C associated with disease severity in coronavirus disease 2019

The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus

Enhanced survival of lung tissue-resident memory CD8⁺ T cells during infection with influenza virus due to selective expression of IFITM3

Comprehensive analysis of two potential novel SARS-CoV-2 entries, TMPRSS2 and IFITM3, in healthy individuals and cancer patients

Mutations and polymorphisms in genes involved in the infections by covid 19: a review

SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype

ACEIs and ARBs and their correlation with COVID-19: a review

Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19

Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers

Genetic association of ACE2 rs2285666 polymorphism with COVID-19 spatial distribution in India

The expression and polymorphism of entry machinery for COVID-19 in human: juxtaposing population groups, gender, and different tissues

Transmembrane serine protease 2 polymorphisms and susceptibility to severe acute respiratory syndrome coronavirus type 2 infection: a German casecontrol study

Strong correlation between the case fatality rate of COVID-19 and the rs6598045 single nucleotide polymorphism (SNP) of the interferon-induced transmembrane protein 3 (IFITM3) gene at the population-level

Common variants at 21q22. 3 locus influence MX1 gene expression and susceptibility to severe COVID-19. iScience

Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

Assessment of risk conferred by coding and regulatory variations of TMPRSS2 and CD26 in susceptibility to SARS-CoV-2 infection in human

The interferoninduced transmembrane protein 3 gene (IFITM3) rs12252 C variant is associated with COVID-19

Interleukin-6 as a potential predictor of COVID-19 disease severity in hospitalized patients and its association with clinical laboratory routine tests

Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID-2019) in 23 countries

HLA, immune response, and susceptibility to COVID-19

Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies

The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis. medRxiv

A key role for vitamin D binding protein in COVID-19?

The role of DBP gene polymorphisms in the prevalence of new coronavirus disease 2019 infection and mortality rate

An evidence for correlation between the glutathione Stransferase T1 (GSTT1) polymorphism and outcome of COVID-19

Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection

SARS-CoV-2 receptor and regulator of the reninangiotensin system: celebrating the 20th anniversary of the discovery of ACE2

Angiotensin-converting enzyme 2: a protective factor in regulating disease virulence of SARS-COV-2

The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections

Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan

ACE2 expression and sex disparity in COVID-19

Effects of host genetic variations on response to, susceptibility and severity of respiratory infections

ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy

Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov. medRxiv

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation

COVID-19: the influence of ACE genotype and ACE-I and ARBs on the course of SARS-CoV-2 infection in elderly patients

ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: an epidemiological study in the Asian population

Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility

Analysis of ACE2 genetic variability among populations highlights a possible link with COVID-19-related neurological complications

COVID-19 infections are also affected by human ACE1 D/I polymorphism

ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in Madrid, Spain

Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients

Angiotensin-converting enzyme 2: the first decade

COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males?

The vasoprotective axes of the reninangiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases

Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients

DPP4, the middle east respiratory syndrome coronavirus receptor, is upregulated in lungs of smokers and chronic obstructive pulmonary disease patients

Assessment of risk conferred by coding and regulatory variations of TMPRSS2 and CD26 in susceptibility to SARS-CoV-2 infection in human

Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity

Emerging roles of dipeptidyl peptidase-4 inhibitors in delaying the progression of type 1 diabetes mellitus

Circulating levels of soluble dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections

Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis

Association of DPP4 gene polymorphisms with type 2 diabetes mellitus in Malaysian subjects

The influence of IFITM3 polymorphisms on susceptibility to SARS-CoV-2 infection and severity of COVID-19

The broad-spectrum antiviral functions of IFIT and IFITM proteins

Antiviral protection by IFITM3 in vivo

IFITM3 restricts the morbidity and mortality associated with influenza

Distinct patterns of IFITMmediated restriction of filoviruses, SARS coronavirus, and influenza A virus

Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2

Strong correlation between the case fatality rate of COVID-19 and the rs6598045 single nucleotide polymorphism (SNP) of the interferon-induced transmembrane protein 3 (IFITM3) gene at the population-level

SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans

Interferon-induced transmembrane protein 3 related to coronavirus disease 2019

Coronavirus disease 2019 (COVID-19): a literature review

Genetic variants that influence SARS-CoV-2 receptor TMPRSS2 expression among population cohorts from multiple continents

Identification of TMPRSS2 as a susceptibility gene for severe 2009 pandemic A(H1N1) influenza and A(H7N9) influenza

Genetic Polymorphism in Glutathione Transferases (GST): population distribution of GSTM1, T1, and P1 conjugating activity

Glutathione S-transferase polymorphisms and their biological consequences

Glutathione S-transferase is a good biomarker in acrylamide induced neurotoxicity and genotoxicity

Association of GSTM1 and GSTT1 gene polymorphisms with COVID-19 susceptibility and its outcome

Glutathione Stransferase gene polymorphisms (GSTT1 and GSTM1) and risk of schizophrenia: a case-control study in Chinese Han population

Blood group ABO polymorphism inhibits SARS-CoV-2 infection and affects COVID-19 progression

ABO blood group and susceptibility to severe acute respiratory syndrome

Relationship between the ABO blood group and the COVID-19 susceptibility

Associations between blood type and COVID-19 infection, intubation, and death

Association between ABO blood groups and clinical outcome of coronavirus disease 2019: evidence from two cohorts. medRxiv

Association between ABO blood groups and risk of SARS-CoV-2 pneumonia

Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients

Association between ABO blood groups and COVID-19 infection, severity and demise: a systematic review and meta-analysis

The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis. medRxiv

Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach

IL-6 in inflammation, immunity, and disease

SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc

Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome

Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study

Complex immune dysregulation in COVID-19 patients with severe respiratory failure

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan

Interleukin-6 as a potential biomarker of COVID-19 progression

Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia

Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans

Genetic polymorphisms mediating behavioural and immune response to pathogens may moderate the impact of the COVID-19 pandemic: a pilot study

Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions

Vitamin D and DBP: the free hormone hypothesis revisited

25-hydroxyvitamin D levels are associated with multiple sclerosis in Iran: a cross-sectional study

A genetic insight into vitamin D binding protein and COVID-19

Associations of vitamin D binding protein variants with the vitamin D-induced increase in serum 25-hydroxyvitamin D

Systematic review and metaanalysis to establish the association of common genetic variations in vitamin D binding protein with chronic obstructive pulmonary disease

Vitamin D binding protein polymorphisms influence susceptibility to hepatitis C virus infection in a high-risk Chinese population

The associations of 25-hydroxyvitamin D levels, vitamin D binding protein gene polymorphisms, and race with risk of incident fracture-related hospitalization: twenty-year follow-up in a bi-ethnic cohort (the ARIC Study)

25-hydroxyvitamin D levels, vitamin D binding protein gene polymorphisms and incident coronary heart disease among whites and blacks: the ARIC study

Polymorphisms in the GC gene for vitamin D binding protein and their association with vitamin D and bone mass in young adults

The role of DBP gene polymorphisms in the prevalence of new coronavirus disease 2019 infection and mortality rate

Role of genetic variants and host polymorphisms on COVID-19: From viral entrance mechanisms to immunological reactions